

March 18, 2015



Trevena CMO to Present at the BioCentury 22nd Annual Future Leaders in the Biotech Industry conference

KING OF PRUSSIA, Pa.--(BUSINESS WIRE)-- Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company, today announced David Soergel, M.D., its chief medical officer, will present a company overview at the BioCentury 22nd Annual Future Leaders in the Biotech Industry conference on Friday March 20, 2015 at 3:00 p.m. EDT in New York.

To access the live audio webcast of the presentation, please visit the "Investors" section of the Company's website at www.trevenainc.com. Following the conclusion of the presentation, the webcast will be archived for 30 days.

About Trevena

Trevena, Inc. is a clinical stage biopharmaceutical company that discovers, develops and intends to commercialize therapeutics that use a novel approach to target G protein coupled receptors, or GPCRs. Using its proprietary product platform, Trevena is developing four biased ligand product candidates it has identified - TRV027 to treat acute heart failure (Phase 2b), TRV130 to treat moderate to severe acute pain intravenously (Phase 2b), TRV734 to treat moderate to severe acute and chronic pain orally (Phase 1), and TRV250 for treatment-refractory migraine and other CNS disorders (Preclinical).

Investor Contacts:

Trevena, Inc.
Jonathan Violin
Director of investor relations
610-354-8840 x231
jviolin@trevenainc.com

or

Argot Partners
Andrea Rabney
President and chief executive officer
212-600-1902
andrea@argotpartners.com

or

Media Contact:

Argot Partners
Eliza Schleifstein
917-763-8106
eliza@argotpartners.com

Source: Trevena, Inc.

